MedPath

Productos Medicos Promedon Chile S.A.

🇨🇱Chile
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:2
Completed:0

Trial Phases

1 Phases

Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (100.0%)

Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Recruiting
Conditions
Pelvic Organ Prolapse
First Posted Date
2021-09-13
Last Posted Date
2024-11-22
Lead Sponsor
Promedon
Target Recruit Count
140
Registration Number
NCT05042453
Locations
🇩🇪

DRK Hospital Chemnitz-Rabenstein, Chemnitz, Germany

🇩🇪

University Hospital Freiburg, Freiburg, Germany

🇩🇪

Clinic Kassel, Kassel, Germany

and more 4 locations

New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis

Not Applicable
Active, not recruiting
Conditions
Pain
Osteoarthritis, Knee
First Posted Date
2019-08-20
Last Posted Date
2022-12-29
Lead Sponsor
Promedon
Target Recruit Count
50
Registration Number
NCT04061733
Locations
🇦🇷

CEMIC, Buenos Aires, Argentina

🇦🇷

DOM Centro de Reumatología, Buenos Aires, Argentina

🇦🇷

IADT, Buenos Aires, Argentina

Prospective Long-term Evaluation of the Efficacy and Safety of Calistar S for Transvaginal Pelvic Organ Prolapse Repair

Not Applicable
Active, not recruiting
Conditions
Pelvic Organ Prolapse
First Posted Date
2019-01-29
Last Posted Date
2024-11-22
Lead Sponsor
Promedon
Target Recruit Count
180
Registration Number
NCT03821142
Locations
🇩🇪

Helios Hospital Erfurt, Department of gynaecology, Erfurt, Thüringen, Germany

🇩🇪

St. Hedwig Hospital, Berlin, Germany

🇩🇪

Evangelic Diakonie Hospital, Freiburg, Germany

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.